Micah Piske1,2, Matthew A Budd1, Annie Q Qiu3, Evelyn J Maan3, Laura J Sauvé3,4, John C Forbes3,4, Ariane Alimenti3,4, Patricia Janssen5,6, Hélène C F Côté1,6. 1. Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. 3. Oak Tree Clinic, BC Women's Hospital and Health Centre. 4. Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. 5. School of Population and Public Health, University of British Columbia. 6. Women's Health Research Institute.
Abstract
OBJECTIVES: To assess and compare neurodevelopmental disorders in HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU) children in British Columbia, Canada. To determine associations between these outcomes and in-utero exposure to antiretroviral drugs. DESIGN: Retrospective controlled cohort study. METHODS: Data were collected on 446 HEU children and 1323 HUU children (matched ∼1 : 3 for age, sex, and geocode) born between 1990 and 2012. Multivariable logistic regressions determined odds ratios of neurodevelopmental disorder diagnoses. RESULTS: HEUs had three times higher odds of being born preterm (P < 0.0001), and a more than two-fold increase in odds for autism, disturbance of emotions, hyperkinetic syndrome, and developmental delay compared with matched HUUs (P < 0.02) in unadjusted analysis. This association was reduced [adjusted neurodevelopmental disorder odds ratio (AOR) = 1.67; 95% confidence interval: 1.12-2.48; P = 0.011] after adjusting for maternal substance use and/or smoking (children born after April 2000). Regardless of antiretroviral exposure type (i.e. none, treatment with one or multiple drug classes), HEUs had higher odds of any neurodevelopmental disorders compared with matched HUUs; however, there was no evidence suggesting any specific classes of antiretroviral drugs or exposure durations increased their likelihood of neurodevelopmental disorders. CONCLUSION: The results suggest no adverse associations between antiretroviral drugs and neurodevelopmental disorders within antiretroviral-exposed HEU children in our cohort. Prevalence of neurodevelopmental disorders is higher in HEUs; however, maternal substance use plays a role, as could other environmental factors not captured. These findings highlight a need for holistic support for pregnant women as well as careful developmental monitoring of HEUs past infancy, and access to early interventions, particularly among those born preterm and those exposed to addictive substances.
OBJECTIVES: To assess and compare neurodevelopmental disorders in HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU) children in British Columbia, Canada. To determine associations between these outcomes and in-utero exposure to antiretroviral drugs. DESIGN: Retrospective controlled cohort study. METHODS: Data were collected on 446 HEU children and 1323 HUU children (matched ∼1 : 3 for age, sex, and geocode) born between 1990 and 2012. Multivariable logistic regressions determined odds ratios of neurodevelopmental disorder diagnoses. RESULTS: HEUs had three times higher odds of being born preterm (P < 0.0001), and a more than two-fold increase in odds for autism, disturbance of emotions, hyperkinetic syndrome, and developmental delay compared with matched HUUs (P < 0.02) in unadjusted analysis. This association was reduced [adjusted neurodevelopmental disorder odds ratio (AOR) = 1.67; 95% confidence interval: 1.12-2.48; P = 0.011] after adjusting for maternal substance use and/or smoking (children born after April 2000). Regardless of antiretroviral exposure type (i.e. none, treatment with one or multiple drug classes), HEUs had higher odds of any neurodevelopmental disorders compared with matched HUUs; however, there was no evidence suggesting any specific classes of antiretroviral drugs or exposure durations increased their likelihood of neurodevelopmental disorders. CONCLUSION: The results suggest no adverse associations between antiretroviral drugs and neurodevelopmental disorders within antiretroviral-exposed HEU children in our cohort. Prevalence of neurodevelopmental disorders is higher in HEUs; however, maternal substance use plays a role, as could other environmental factors not captured. These findings highlight a need for holistic support for pregnant women as well as careful developmental monitoring of HEUs past infancy, and access to early interventions, particularly among those born preterm and those exposed to addictive substances.
Authors: Abhinav Ajaykumar; Mayanne Zhu; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Hugo Soudeyns; Sara Saberi; Arianne Y K Albert; Deborah M Money; Hélène C F Côté Journal: J Infect Dis Date: 2021-02-24 Impact factor: 5.226
Authors: Joanah Madzime; Martha Holmes; Mark F Cotton; Barbara Laughton; Andre J W van der Kouwe; Ernesta M Meintjes; Marcin Jankiewicz Journal: Brain Connect Date: 2021-08-23
Authors: Megan S McHenry; Kayode A Balogun; Brenna C McDonald; Rachel C Vreeman; Elizabeth C Whipple; Lena Serghides Journal: J Int AIDS Soc Date: 2019-04 Impact factor: 6.707
Authors: Clara E Van Ommen; Arianne Y K Albert; Micah Piske; Deborah M Money; Hélène C F Cote; Viviane D Lima; Evelyn J Maan; Ariane Alimenti; Julianne van Schalkwyk; Neora Pick; Melanie C M Murray Journal: PLoS One Date: 2019-02-06 Impact factor: 3.240
Authors: Ambalika Sarkar; Kayode Balogun; Monica S Guzman Lenis; Sebastian Acosta; Howard T Mount; Lena Serghides Journal: PLoS One Date: 2020-11-19 Impact factor: 3.240
Authors: Jorem Emmillian Awadu; Alla Sikorskii; Sarah Zalwango; Audrey Coventry; Bruno Giordani; Amara E Ezeamama Journal: Int J Environ Res Public Health Date: 2022-03-21 Impact factor: 3.390